Latest Interviews
Showing 1–15 of 23 transcripts.
Clear all filters- a16z46 min
Hey Tech, Come to Healthcare
In a 2022 analysis, analysts BJ and Daisy predict that consumer health technology will produce the world's first trillion-dollar company by leveraging a $4 trillion U.S. market where 88% of the population faces metabolic challenges. The event details how artificial intelligence and post-pandemic cultural shifts are enabling a transition from reactive sick care to predictive, home-centric prevention while bypassing traditional incumbent barriers through new "payvider," marketplace, and financial infrastructure models. These strategies aim to unify fragmented health data and engineer behavioral change, ultimately positioning tech founders with hybrid clinical expertise to replace legacy systems with AI-driven, high-UX solutions.
- a16z21 min
7 More Healthy Years: What We Can Learn from Super Agers
The proposed healthcare strategy shifts focus from unproven aging reversal to preventing the "big three" age-related diseases through modifiable lifestyle factors and emerging medical technologies. By integrating personalized omics data, AI-driven risk profiling, and novel treatments like GLP-1 drugs and cellular therapies, this approach aims to extend healthspan by seven years for populations globally. This evidence-based framework prioritizes immediate disease mitigation over theoretical longevity, leveraging a 20-year incubation window to fundamentally redefine the standard of care.
- a16z35 min
Implementation, Data, Impact of Healthcare AI with Julie and Vijay
Industry leaders project that AI agents will reduce healthcare costs by up to 50% through labor arbitrage and prevention-focused value-based care, while simultaneously compressing training times from months to days. Despite these economic advantages, widespread adoption faces significant hurdles including regulatory ambiguity over AI credentialing, the inelastic nature of healthcare demand, and the critical need to shift from retrospective records to prospective data generation. To overcome these barriers, organizations are reclassifying technology as labor, utilizing AI as a recruitment tool to reduce clinician burnout, and transitioning toward hybrid models where human oversight manages complex exceptions while automated systems handle routine phenotyping and triage.
- a16z38 min
Grand Challenges in Healthcare AI with Vijay Pande and Julie Yoo
Amidst a healthcare labor crisis and provider burnout, AI adoption is accelerating through administrative efficiencies in revenue cycle management and the digitization of complex payer-provider contracts. Strategic startups are targeting near-term opportunities by embedding natural language interfaces into existing Electronic Health Records, automating prior authorization, and restructuring clinical trials through real-world data analysis. While full-stack AI clinicians remain a distant goal, the immediate landscape prioritizes behavioral change strategies, unbundled care roles, and value-based care alignment to optimize patient outcomes and reduce systemic waste.
- a16z30 min
Fireside Chat with Sean Duffy
Amada Health, rebranding as Raising Health, recently celebrated reaching one million patients by leveraging a proprietary dataset of 25 million messages to deploy AI that augments care teams while addressing the limitations of GLP-1 medications through a dedicated lifestyle track. Co-founder Sean Duffy highlights how the company evolved from skepticism about "provider without clinics" into a foundational digital infrastructure that utilizes artificial empathy to mitigate provider shortages and lower long-term healthcare costs. By pivoting from pure software replication to a hybrid tech-life sciences model, the organization now positions itself as an essential "between-visit" partner capable of offloading longitudinal management from overwhelmed primary care clinicians.
- a16z22 min
Digital Biology with insitro's Daphne Koller
In-Citro, founded by Coursera co-creator Daphne Koller, is deploying a "data factory" model that uses CRISPR-edited human pluripotent stem cells to systematically generate genetic variance data for drug discovery. The company's proprietary POSH platform and multimodal biology language models analyze hundreds of millions of cells to identify disease mechanisms and predict therapeutic interventions, effectively replacing error-prone murine testing with human-derived systems. Koller aims to deliver a first tranche of medicines to patients by the end of the decade while extending this digital biology framework to address global challenges in agriculture and environmental sustainability.
- a16z1h 12m
2023 Big Ideas in Technology (Part 2)
Anish Acharya, Angela Strange, Michelle Volz, Ryan McEntush, Vijay Pande, Julie Yoo
Anish Charya and Angela Strange outline transformative fintech strategies where GPT-driven credit counseling scales labor efficiency while software-enabled compliance converts regulatory burdens into strategic competitive moats. Parallel discussions led by Michelle Foles and Ryan McIntosh highlight how Small Modular Reactors and space supply chain overhauls will redefine energy production and industrial supremacy through advanced manufacturing and resource extraction. These innovation themes converge with healthcare predictions from Vijay Pandey and Julie Yu, who forecast the rise of consumer health tech and value-based care stacks to replace legacy fee-for-service models with outcome-focused infrastructure.
- a16z44 min
Food, Drugs, and Tech: 100 years of Public Health
Established in 1906 to address public health crises, the FDA is currently transitioning its 20% GDP-regulated portfolio from legacy physical archives to a fully digital, data-informed infrastructure that leverages machine learning for food safety and pathogen tracking. While modernizing clinical trial frameworks through the 21st Century Cures Act to accommodate gene therapies and real-world evidence, the agency balances risk aversion with the urgent need to approve life-saving innovations like cell-cultured foods and AI-driven medical devices. This evolution positions the FDA to shift from reactive disease treatment to preventative longitudinal care, utilizing synthetic data and dynamic regulatory paradigms to manage emerging biological technologies over the next century.
- a16z36 min
a16z Podcast | Dark Data in Healthcare
Susannah Fox, Anil Sethi, Vijay Pande, Sonal Chokshi
A speaker outlines a paradigm shift in healthcare where the legal right of "Portability" under HIPAA transforms patients from passive data recipients into the central hubs of their own longitudinal medical records. This approach addresses the "dark data" gap by leveraging real-world evidence and AI to unify fragmented clinical and non-clinical sources, thereby accelerating chronic disease management and clinical trial matching. Ultimately, the proposal envisions a "permissionless innovation" ecosystem where frictionless data access empowers patients to coordinate care across providers and drive collaborative research.
- a16z59 min
a16z Podcast | The Science and Business of Innovative Medicines
Jorge Conde, Vijay Pande, Sonal Chokshi, Vas Narasimhan
Novartis transformed its portfolio through a $50 billion restructuring that divested consumer healthcare to prioritize advanced therapies, data science, and proprietary platforms for cell and gene treatments. Under CEO Vas Narasimhan, the company enforces strict "standard of care" mandates for project approval, integrates market access early in development, and invested $15 billion to own specialized infrastructure while leveraging AI for financial forecasting and pathology analysis. This strategic pivot targets a 10% clinical success rate by shifting from bespoke drug development to modular platforms and dedicated digital innovation centers, positioning the firm to address undruggable targets and future modalities like xenotransplantation.
- a16z8 min
a16z Podcast | On Recent Consolidation in the Healthcare Industry
Jorge Conde, Vijay Pande, Jeffrey Low
Major healthcare players are driving industry consolidation through vertical integration strategies exemplified by Walmart's potential Humana acquisition and the Amazon-JP Morgan-Berkshire consortium. These moves aim to collapse the value chain from manufacturers to insurers, though speakers distinguish between locally dominant retailers and geographically dispersed employer groups regarding their pricing power. As Amazon targets opaque PBM margins without acquiring marquee assets, the market anticipates new entrepreneurial opportunities in specialized genomic and cell therapy logistics to manage rising treatment costs.
- a16z22 min
a16z Podcast | When (and How) Biology Becomes Engineering
The event details the transformative shift in biology from a stochastic, discovery-based science to a standardized engineering discipline that treats biological components as predictable, interchangeable parts. Interdisciplinary innovation and machine learning now drive this transition by enabling repeatable design-build-refine cycles that replace traditional high-risk experimentation with data-driven predictability. This engineering mindset aims to commercialize biological platforms through measurable success rates and sustainable infrastructure, ultimately making previously impossible medical and industrial goals achievable through compounding technological improvements.
- a16z29 min
a16z Podcast | Mindsets for Engineering Biology
Bob Langer, Vijay Pande, Hanne Tidnam, Hannah
This presentation traces the evolution of biomaterials and drug delivery from 20th-century improvisation to modern rational engineering driven by high-throughput automation and robotics. It details how regulatory shifts and the transition to protein and gene therapies have necessitated sophisticated controlled-release systems for treating complex diseases like cancer and diabetes. Looking forward, the industry is pivoting toward regenerative medicine and longevity research, aiming to solve critical challenges in organ engineering and multi-omics data interpretation.
- a16z35 min
a16z Podcast | What Technology Wants, Needs, Does
Marc Andreessen, Frank Chen, Vijay Pande, Alex Rampell
This panel examined critical regulatory tensions in healthcare and fintech, analyzing how the shift to pay-for-value models and Dodd-Frank risk retention rules create new barriers for startups while enabling regulatory arbitrage. Experts further debated the ethical implications of AI in lending and medicine, highlighting the conflict between opaque deep learning algorithms and existing fair-lending laws alongside the potential for technology to render physical travel obsolete through high-fidelity telepresence. The discussion concluded by projecting how innovations in genomic risk scoring, autonomous logistics, and lab-grown organs will fundamentally reshape social determinants of health and long-term human longevity.
- a16z26 min
a16z Podcast | The Rise of the Digital 'Pill'
Sean Duffy, Vijay Pande, Malinka Walaliyadde, Hannah, Malinka Walaliate
Digital health has evolved into a distinct third wave of therapeutics that treats behavioral and metabolic conditions through software-driven clinical interventions validated by rigorous randomized controlled trials. Despite past skepticism from medical authorities, industry leaders are overcoming adoption barriers by demonstrating superior efficacy in areas like diabetes management and shifting payment models toward value-based outcomes. The sector is increasingly integrating with existing healthcare infrastructure to act as a clinical collaborator rather than a replacement, with artificial intelligence poised to deepen this impact while addressing global provider shortages.